低风险MDS患者接受螯合治疗及不接受螯合治疗的24个月结局对比:一项前瞻性注册研究结果

Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry
2014-01-01 13:45点击:766次发表评论
作者:Roger M. Lyons, Billie J. Marek, Carole Paley, Jason Esposito, Lawrence Garbo, Nicholas DiBella, Guillermo Garcia-Manero
期刊: LEUKEMIA RES2013年11月期卷

 

This 5-year, prospective registry enrolled 600 lower-risk MDS patients (pts) with transfusional iron overload. Clinical outcomes were compared between chelated and nonchelated pts. At baseline, cardiovascular comorbidities were more common in non-chelated pts, and MDS therapy was more common in chelated pts. At 24 months, chelation was associated with longer median overall survival (52.2 months vs. 104.4 months; p < .0001) and a trend toward longer leukemia-free survival and fewer cardiac events. No differences in safety were apparent between groups. Limitations of this analysis included, varying time from diagnosis and duration of chelation, and the fact that the decision to chelate may have been influenced by pt clinical status.

 

主要结论:在24个月时,与不接受螯合治疗者相比,接受螯合治疗者的中位整体生存期更长,并具有无白血病生存期更长、心脏不良事件更少的趋势。

学科代码:肿瘤学 血液病学   关键词:MDS;螯合治疗 ,全球精选文摘 爱思唯尔医学网, Elseviermed
来源: 爱思唯尔
爱思唯尔介绍:全球最大的科技医学出版商――爱思唯尔以出版发行高品质的、前沿的科学、技术和医学信息,并保证其满足全世界科技和医学工作者对于信息的需求而著称。现在,公司建立起全球的学术体系,拥有7,000名期刊编辑、70,000名编辑委员会成员、200,000专家审稿人以及500,000名作者,每年出版2,000本期刊和2,200种新书,并拥有17,000种在库图书。 马上访问爱思唯尔网站http://www.elseviermed.cn
顶一下(0
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录